Martin W. MacKay is an American businessperson who founded Rallybio Corp. and Rallybio LLC and who has been at the head of 8 different companies. Currently, Dr. MacKay is Chairman & Chief Executive Officer of Rallybio Corp., Chairman & Chief Executive Officer at Rallybio LLC and Chief Executive Officer & Director at Rallybio Holdings LLC (both are subsidiaries of Rallybio Corp.), Chief Executive Officer of Calyx Group Ltd. (Ireland) and Senior Advisor at New Leaf Venture Partners LLC.
He is also on the board of Charles River Laboratories International, Inc., Charles River Laboratories, Inc., Novo Nordisk An and 5:01 Acquisition Corp.
In the past Martin W. MacKay occupied the position of Chief Executive Officer & Director at Neverfail, Inc. and Chief Executive Officer & Director at Neverfail Group Ltd. (a subsidiary of Neverfail, Inc.), Senior Vice President-Worldwide Development at Pfizer Inc. and President at Pfizer (St. Louis) (a subsidiary of Pfizer Inc.), President-Research & Development at AstraZeneca Plc and Global Head-Research & Development at Alexion Pharmaceuticals, Inc. (a subsidiary of AstraZeneca Plc), Vice President-International at VeriSign, Inc., Principal at PeopleSoft USA, Inc., Principal at Beecham Pharmaceuticals (UK), Chief Executive Officer at Vecta Software Corp. Ltd., Operations Director at The Dun & Bradstreet Corp., Head-Drug Preformulation & Delivery at BASF Performance Products Ltd. (United Kingdom), Head-Molecular & Cell Biology at CRI Worldwide LLC, Principal at Accenture LLC, Director-Business Development at NorthgateArinso, Inc. and Head-Drug Preformulation & Delivery at Ciba-Geigy Pharmaceuticals.
Martin W. MacKay received an undergraduate degree from Heriot-Watt University and a doctorate from The University of Edinburgh.